Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax, Rituximab and Nivolumab Combination in Patients With Richter's Transformation (RT) Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Phase II Study With Safety Run-In

NCT06247540 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT06247540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06247540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax, Rituximab and Nivolumab Combination in Patients With Richter's Transformation (RT) Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Phase II Study With Safety Run-In
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Withdrawn
Start date
March 29, 2024
Completion date
December 29, 2031
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent transformed chronic lymphocytic leukemia, refractory transformed chronic lymphocytic leukemia, richter syndrome, transformed chronic lymphocytic leukemia to diffuse large b-cell lymphoma, transformed small lymphocytic lymphoma to diffuse large b-cell lymphoma